← All sarcoma trials
Recruiting nowPhase 1Ages 18 Years and up

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

Sponsor: Bristol-Myers Squibb · NCT05245500 on ClinicalTrials.gov ↗

Bring this to your care team →

Conditions studied

MesotheliomaNon Small Cell Lung CancerMalignant Peripheral Nerve Sheath TumorsSolid TumorPancreatic AdenocarcinomaAdvanced Solid Tumor

What it tests

  • MRTX1719drug

Where it's running25 sites

  • Mayo Clinic

    Phoenix, Arizona 85054-4502

    Recruiting now

  • Sarah Cannon Research Institute (SCRI) - HealthONE Location

    Denver, Colorado 80218-1238

    Recruiting now

  • Rocky Mountain Cancer Centers, LLP - Oncology

    Lone Tree, Colorado 80124

    Recruiting now

  • Mayo Clinic

    Jacksonville, Florida 32224

    Recruiting now

  • Sarah Cannon Research Institute at Florida Cancer Specialists

    Orlando, Florida 32827

    Recruiting now
    • Cesar Perez Batista, Site 121(contact)

  • Local Institution - 124

    Chicago, Illinois 60637

    Withdrawn

  • Dana-Farber Cancer Institute

    Brookline, Massachusetts 02251

    Recruiting now

  • Cancer and Hematology Centers of Western Michigan

    Norton Shores, Michigan 49444

    Recruiting now

  • Mayo Clinic

    Rochester, Minnesota 55905

    Recruiting now

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey 08901

    Recruiting now

  • Local Institution - 129

    Mineola, New York 11501

    Opening soon
    • Site 129(contact)

  • David H Koch, Memorial Sloan Kettering Cancer Center

    New York, New York 10021

    Recruiting now

  • New york cancer and blood specialists - Oncology

    Port Jefferson Station, New York 11776

    Recruiting now

  • New york cancer and blood specialists - Oncology

    Port Jefferson Station, New York 11776

    Recruiting now
    • Richard Zuniga, Site 115(contact)

  • University of North Carolina - Gastroenterology and Hepatology

    Chapel Hill, North Carolina 27599

    Recruiting now
    • Shetal Patel, Site 107(contact)

  • University of North Carolina

    Chapel Hill, North Carolina 27599

    Recruiting now
    • Shetal Patel, Site 125(contact)

  • Vanderbilt - Ingram Cancer Center

    Nashville, Tennessee 37232-5505

    Recruiting now

  • Ut Southwestern

    Dallas, Texas 75235

    Recruiting now
    • Salwan Al Mutar, Site 120(contact)

  • Texas Oncology - DFW

    Fort Worth, Texas 76104

    Recruiting now

  • MDACC

    Houston, Texas 77030

    Recruiting now
    • Jordi Ahnert, Site 105(contact)

  • South Texas Accelerated Research Therapeutics

    San Antonio, Texas 78229

    Recruiting now
    • Kyriakos Papadopoulos, Site 102(contact)

  • Texas Oncology, P.A. - Oncology

    Tyler, Texas 78503

    Recruiting now

  • Virginia Cancer Specialists, PC

    Fairfax, Virginia 22031

    Recruiting now

  • Local Institution - 134

    Seattle, Washington 98109

    Withdrawn

  • Local Institution - 108

    Milwaukee, Wisconsin 53226

    Completed
See the official eligibility language

Shown exactly as written on ClinicalTrials.gov. Your oncologist is the right person to judge whether it fits your situation.

Inclusion Criteria

* Histologically confirmed diagnosis of a solid tumor malignancy with homozygous deletion of the MTAP gene detected in tumor tissue.
* Unresectable or metastatic disease.
* Presence of a tumor lesion amenable to mandatory biopsy for pharmacodynamic evaluation at baseline and on-study unless Sponsor-confirmed as medically unsafe or infeasible.
* Age ≥ 18 years.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
* Adequate organ function.

Exclusion Criteria

* Prior treatment with a PRMT5 or MAT2A inhibitor therapy.
* Active brain metastases or carcinomatous meningitis.
* History of significant hemoptysis or hemorrhage within 4 weeks of the first dose of study treatment.
* Major surgery within 4 weeks of first dose of study treatment.
* History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions (eg, uncontrolled nausea, vomiting, malabsorption syndrome) likely to alter absorption of study treatment or result in inability to swallow oral medications.
* Cardiac abnormalities.
* Other protocol-defined Inclusion/Exclusion criteria apply.

Updated 2025-12-05 on ClinicalTrials.gov. Always confirm current details with the study team or your oncologist.